



PATENT

Customer No. 22,852  
Attorney Docket No. 04853.0086

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Etsuro OGATA et al. ) Group Art Unit: 1743  
Application No.: 10/019,571 ) Examiner: Not Yet Assigned  
International Filing Date: July 3, 2000 )  
§ 371 Date: December 31, 2001 )  
For: THERAPEUTIC AGENT FOR )  
DISEASES CAUSED BY PTH OR )  
PTHrP )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

RECEIVED

SEP 12 2003

TECH CENTER 1600/2900

RECEIVED  
SEP 05 2003  
GROUP 1700

Sir:

**SECOND SUPPLEMENTAL INFORMATION**  
**DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the document listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

A copy of the listed document is attached. Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making an appropriate notation on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

PATENT  
Customer No. 22,852  
Application No. 10/019,571  
Attorney Docket No. 04853.0086

documents are material or constitute "prior art." If the Examiner applies the document as prior art against any claims in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: September 4, 2003

By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

## **INFORMATION DISCLOSURE CITATION**

Atty. Docket No.	4853.0086-00	Appln. No.	10/019,571
Applicant	OGATA et al.		
International Filing Date	Group: 1743 July 3, 2000		

## U.S. PATENT DOCUMENTS

RECEIVED  
SEP 05 2003  
GROUP 1700

## **FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
							RECEIVED
							SEP 12 2003

**RECEIVED**

SFP 12 2003

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) TECH CENTER 1600/2900

Sabatini et al., "Increased Production of Tumor Necrosis Factor by Normal Immune Cells in a Model of the Humoral Hypercalcemia of Malignancy," *Laboratory Investigation*, 63(5), 676-682 (1990).

Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.